查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2098972

中樞神經系統生物標記市場－2026-2032年全球市場預測

Central Nervous System Biomarkers Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，中樞神經系統 (CNS) 生物標記市場將成長至 106.6 億美元，複合年成長率為 7.63%。

主要市場統計數據
基準年 2025 63.7億美元
預計年份：2026年 68.4億美元
預測年份：2032年 106.6億美元
複合年成長率 (%) 7.63%

執行摘要

中樞神經系統生物標記是可測量的生物學指標，用於輔助神經系統和精神疾病的檢測、診斷、預後、後續觀察和療效評估。這些生物標記包括腦脊髓液和血液中的分子訊號、神經影像學指標、電生理測量、數位行為標記、遺傳和蛋白質組學特徵以及新興的多體學譜。調查計畫和神經病學調查計畫報告顯示，阿茲海默症、帕金森氏症、多發性硬化症、癲癇、中風、創傷性腦損傷、重度憂鬱症和其他中樞神經系統疾病的負擔日益加重，醫療保健系統也隨之加大了對這些生物標記的臨床應用。

中樞神經系統生物標記片段的變革性變化

隨著研究從單一分析物模型轉向整合體液、影像、遺傳、電生理和數位訊號的綜合生物標記組合，中樞神經系統生物標記領域正經歷變革。血液來源的生物標記作為一種侵入性較小的腦脊髓液採樣替代方案，正吸引臨床的廣泛關注，並有望實現可擴展的篩檢、分流和縱向監測。在阿茲海默症研究中，經過同行評審的研究表明，血漿磷酸化Tau、BETA-澱粉樣蛋白比值、膠質纖維酸性蛋白和神經絲輕鏈與神經退化、澱粉樣蛋白病理、 Tau蛋白病理和疾病進展密切相關，這加速了它們在臨床應用方面的評估。

人工智慧對中樞神經系統生物標記的累積影響

人工智慧正在變革中樞神經系統生物標記的發現、檢驗和實用化，其實現對複雜生物和臨床資料集的模式識別至關重要。機器學習模型正被應用於神經影像學、基因組學、蛋白質組學、代謝體學、電子健康記錄、語音模式、運動數據和數字認知功能評估等領域，識別出傳統統計方法可能遺漏的疾病特徵。在放射學和神經科學研究中，人工智慧驅動的影像分析支援自動分割、病灶量化、腦萎縮評估、連接性分析以及對細微結構和功能變化的檢測。

關於中樞神經系統生物標記的關鍵區域性見解

由於人口老化、神經科學研究基礎設施的不斷完善，以及中國、日本、韓國、印度和澳洲等國神經退化性疾病診斷數量的增加，亞太地區在中樞神經系統生物標記開發方面的重要性日益凸顯。這一發展勢頭得益於日本長期以來對失智症護理和神經影像學的重視、韓國的數位醫療能力、中國大規模的臨床研究網路、印度不斷提升的診斷能力以及澳大利亞在隊列研究和神經學研究方面的優勢。然而，該地區也面臨許多挑戰，例如先進診斷技術的可及性存在差異、檢查室標準化程度不同、報銷途徑不統一，以及需要針對特定人群檢驗血液檢測、影像學和數位中樞神經系統生物標記。

主要經濟和戰略群體的見解

北約成員國與北美和歐洲的高能力研究體係高度重合，這些地區軍方和民間對創傷性腦損傷、神經認知健康、心理韌性、睡眠障礙和復原的日益關注，推動了對客觀神經學、行為學和數位生物標記的研究。該研究團隊對於腦震盪評估、創傷後壓力症狀、認知功能監測以及與長期神經系統預後相關的中樞神經系統生物標記的應用尤為重要，但數據安全、互通性和倫理使用方面的嚴格要求阻礙了這些研究成果的實施。

主要國家中樞神經系統生物標記引入趨勢

中國正憑藉其大規模的醫院網路、國家級神經科學舉措、基因組分析能力以及人工智慧驅動的醫療健康研究，迅速拓展中樞神經系統生物標記的研究。美國憑藉其廣泛的臨床實驗室網路、主導的實驗室平台、神經影像學專長、生物生物銀行以及與監管機構在生物標記合格和伴隨診斷核准流程方面的合作，在中樞神經系統生物標記的實用化方面發揮著主導作用。日本是世界上老化程度最高的國家之一，在與老齡化相關的神經科學、失智症診斷、神經影像學和帕金森氏症研究方面擁有深厚的專業知識。印度擁有龐大且多元化的人口、不斷成長的診斷領域以及對神經和精神健康負擔日益成長的關注，因此具有巨大的潛力，但都市區三級醫療機構與農村地區在醫療服務獲取方面的巨大差距仍然是一個嚴峻的挑戰。

中樞神經系統生物標記領域領導者使用的實用建議

產業領導者應優先考慮經臨床驗證的中樞神經系統生物標記解決方案，這些方案應能解決明確的決策點，包括早期檢測、鑑別診斷、預後判斷、治療方案選擇、疾病活動監測、安全性評估以及臨床檢驗的患者篩選。開發策略應從可靠的分析檢驗入手，包括檢測準確性、可重複性、分析前對照、參考物質以及檢查室可比性。臨床檢驗必須反映真實臨床環境中疾病的異質性，包括共病、年齡差異、性別差異、種族差異、藥物效應、疾病階段、醫療服務環境的多樣性。

中樞神經系統生物標記分析的調查方法

本執行摘要採用系統性的二手研究途徑編寫，重點關注與中樞神經系統生物標記相關的檢驗且有數據支持的資訊來源。該調查方法包括審查和整契約行評審的科學文獻、臨床指南、監管出版刊物、公共衛生數據、生物標記合格框架、疾病特異性研究聯盟以及經認證的醫療保健和神經科學機構發布的資訊。優先考慮來自多中心研究、系統綜述、縱向隊列研究、監管科學文件和臨床檢驗的生物標記研究的證據。

結論：基於證據的中樞神經系統生物標記成長

中樞神經系統生物標記正成為神經病學、精神病學和中樞神經系統藥物研發下一階段的基礎。最顯著的進展體現在檢驗的生物指標與明確的臨床決策、標準化的工作流程以及長期病患監測的關聯性。儘管血液來源的生物標記、先進的神經影像學、電生理測量、數位化測量以及人工智慧驅動的多模態分析正在拓展可測量的範圍，但它們的臨床價值取決於其可重複性、可解釋性、公正的檢驗以及與臨床診療路徑的整合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 中樞神經系統生物標記市場：按類型分類

  • 分子生物標記
    • 基於DNA的生物標記
    • 基於RNA的生物標記
    • 基於蛋白質的生物標記
  • 影像生物標記
  • 基因生物標記
  • 數位生物標記
  • 代謝生物標記

第8章 中樞神經系統生物標記市場：依適應症分類

  • 神經退化性疾病
  • 神經發育障礙
  • 精神病性障礙

第9章 中樞神經系統生物標記市場：依技術分類

  • 免疫檢測
    • ELISA生物標記
    • 多重免疫檢測
  • 質譜分析
    • 蛋白質體學分析
    • 代謝體學學分析
  • 下一代定序
    • 全基因組定序
    • RNA定序

第10章 中樞神經系統生物標記市場：依應用領域分類

  • 診斷和治療
  • 藥物發現與開發
  • 個人化醫療
  • 預後
  • 研究與開發

第11章 中樞神經系統生物標記市場：依最終用戶分類

  • 學術研究機構
  • 醫療服務提供方
  • 製藥和生物技術公司
  • 醫院和診所

第12章 中樞神經系統生物標記市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章 中樞神經系統生物標記市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 中樞神經系統生物標記市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Acumen Pharmaceuticals Inc.
  • Agilent Technologies Inc.
  • Alector Inc.
  • Bio-Rad Laboratories Inc.
  • Biogen Inc.
  • C2N Diagnostics
  • Charles River Laboratories International Inc.
  • Eli Lilly and Company
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Fujirebio
  • GE HealthCare Technologies Inc.
  • IQVIA Holdings Inc.
  • Johnson & Johnson Services Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Myriad Genetics Inc.
  • Novartis AG
  • PerkinElmer Inc.
  • QIAGEN NV
  • Quanterix Corp.
  • Revvity Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-450A0628CEB3

The Central Nervous System Biomarkers Market is projected to grow by USD 10.66 billion at a CAGR of 7.63% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.37 billion
Estimated Year [2026] USD 6.84 billion
Forecast Year [2032] USD 10.66 billion
CAGR (%) 7.63%

Central Nervous System Biomarkers Executive Summary

Central nervous system biomarkers are measurable biological indicators used to support the detection, diagnosis, prognosis, monitoring, and therapeutic evaluation of neurological and psychiatric disorders. These biomarkers include molecular signals in cerebrospinal fluid and blood, neuroimaging indicators, electrophysiological measures, digital behavioral markers, genetic and proteomic signatures, and emerging multi-omics profiles. Their clinical relevance is expanding as healthcare systems respond to rising burdens from Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, stroke, traumatic brain injury, major depressive disorder, and other CNS conditions documented by global public health and neurology research programs.

The field is moving from symptom-led assessment toward biomarker-supported precision neurology and precision psychiatry. Regulatory agencies have increasingly emphasized biomarker qualification, real-world evidence, and patient enrichment strategies in CNS drug development, while clinical researchers are prioritizing minimally invasive blood-based biomarkers, standardized imaging protocols, and longitudinal monitoring tools. In parallel, advances in assay sensitivity, neurofilament light chain testing, amyloid and tau detection, synaptic markers, inflammatory biomarkers, and digital cognition tools are improving the ability to identify disease activity earlier and measure progression more objectively.

For industry leaders, the opportunity lies not in broad claims but in validated, clinically interpretable, and workflow-ready biomarker solutions. Successful adoption depends on analytical validity, clinical utility, reimbursement readiness, data interoperability, ethical governance, representative validation cohorts, and demonstrable value in improving patient outcomes and clinical trial efficiency.

Transformative Shifts in the CNS Biomarkers Landscape

The CNS biomarkers landscape is undergoing transformative change as research moves beyond single-analyte models toward integrated biomarker panels that combine fluid, imaging, genetic, electrophysiological, and digital signals. Blood-based biomarkers are drawing strong clinical interest because they offer a less invasive alternative to cerebrospinal fluid sampling and can support scalable screening, triage, and longitudinal monitoring. In Alzheimer's disease research, plasma phosphorylated tau, amyloid-beta ratios, glial fibrillary acidic protein, and neurofilament light chain have shown strong associations with neurodegeneration, amyloid pathology, tau pathology, and disease progression in peer-reviewed studies, accelerating their evaluation for clinical use.

Clinical trials are also shifting. Biomarkers are increasingly used for participant selection, target engagement, pharmacodynamic assessment, safety monitoring, and stratification of heterogeneous CNS populations. This is especially important because CNS disorders often present with overlapping symptoms and variable disease trajectories. Biomarker-guided trial designs can reduce diagnostic uncertainty, support earlier intervention, and improve the interpretability of therapeutic response.

Healthcare delivery is evolving as well. Neurology practices, memory clinics, academic hospitals, and specialized laboratories are adopting more standardized protocols for sample handling, imaging interpretation, and cognitive assessment. At the same time, digital biomarkers collected through wearables, smartphones, speech analysis, gait assessment, sleep monitoring, and passive activity tracking are creating new opportunities for remote measurement of motor, cognitive, and behavioral changes. The strongest shift is toward evidence-linked biomarker ecosystems that can connect laboratory data, imaging data, clinical records, and real-world patient monitoring into actionable decision support.

Cumulative Impact of Artificial Intelligence on CNS Biomarkers

Artificial intelligence is reshaping CNS biomarker discovery, validation, and deployment by enabling pattern recognition across complex biological and clinical datasets. Machine learning models are being applied to neuroimaging, genomics, proteomics, metabolomics, electronic health records, speech patterns, movement data, and digital cognitive assessments to identify disease signatures that may not be visible through conventional statistical methods. In radiology and neuroscience research, AI-assisted image analysis supports automated segmentation, lesion quantification, brain atrophy assessment, connectivity analysis, and detection of subtle structural or functional changes.

The cumulative impact of AI is particularly important in disorders with high biological heterogeneity, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, and major psychiatric conditions. AI can support multimodal biomarker panels by integrating fluid markers with imaging, clinical scales, medication history, genetics, environmental exposure data, and longitudinal outcomes. This creates potential for more precise phenotyping, earlier risk identification, and better prediction of disease progression.

However, AI adoption in CNS biomarkers requires disciplined governance. Models must be trained on diverse and representative datasets, externally validated, monitored for bias, and aligned with clinical interpretability standards. Data privacy, cybersecurity, explainability, and regulatory traceability are essential, particularly when AI outputs influence diagnosis, trial eligibility, or treatment monitoring. The most sustainable AI strategies will combine high-quality annotated data, transparent model development, clinician oversight, and evidence of measurable improvement in clinical or research decision-making.

Key Regional Insights Across CNS Biomarkers

Asia-Pacific is becoming an increasingly important region for CNS biomarker development due to aging populations, expanding neuroscience research infrastructure, and rising diagnosis of neurodegenerative disorders in China, Japan, South Korea, India, and Australia. Japan's long-standing focus on dementia care and neuroimaging research, South Korea's digital health capabilities, China's large-scale clinical research networks, India's growing diagnostics capacity, and Australia's strength in cohort studies and neurological research collectively support regional momentum. The region also faces challenges related to uneven access to advanced diagnostics, differences in laboratory standardization, variability in reimbursement pathways, and the need for population-specific validation of blood-based, imaging, and digital CNS biomarkers.

Europe is characterized by strong regulatory coordination, cross-border research networks, and established expertise in neurology, psychiatry, imaging, and biomarker standardization. The region's emphasis on data protection, ethical research, in vitro diagnostic regulation, and clinical evidence generation shapes biomarker adoption. Germany, France, Italy, Spain, the United Kingdom, and Nordic research ecosystems support advances in dementia, multiple sclerosis, Parkinson's disease, epilepsy, and psychiatric biomarker studies, while harmonized research frameworks strengthen multicenter validation and real-world evidence collection.

North America remains highly influential in CNS biomarker research because of its concentration of academic medical centers, specialized neurology networks, biobanks, regulatory science initiatives, and clinical trial activity. The United States has been central to Alzheimer's disease biomarker research, neurofilament light chain evaluation, advanced imaging protocols, and digital biomarker development, while Canada contributes through population health research, neuroscience collaboration, and public health-linked neurological datasets. Adoption is supported by advanced laboratory infrastructure, although payer evidence requirements, clinical implementation standards, and equitable access remain critical factors.

Latin America is building capacity in CNS biomarker research as neurological disease burden rises and regional centers increase participation in clinical studies. Brazil and Mexico are key contributors due to their academic hospitals, growing genomics and diagnostics capabilities, and large patient populations. However, disparities in specialist access, limited availability of advanced neuroimaging in some areas, fragmented reimbursement structures, and underrepresentation in global biomarker cohorts can slow routine clinical integration.

Africa presents an important long-term opportunity for CNS biomarker research due to genetic diversity, infectious and noncommunicable neurological disease intersections, and growing academic partnerships. Limited laboratory infrastructure, unequal access to neurologists, and underrepresentation in global biomarker datasets highlight the need for inclusive research models, sustainable capacity building, and locally relevant validation. The Middle East is expanding its neuroscience and precision medicine capabilities through investments in tertiary care, genomics, and specialized diagnostic infrastructure, particularly in Gulf countries. Growth is supported by healthcare modernization and interest in advanced neurological care, but local validation, workforce development, and integrated care pathways remain priorities.

Key Economic and Strategic Group Insights

NATO countries overlap substantially with high-capacity research systems in North America and Europe, where military and civilian interest in traumatic brain injury, neurocognitive health, mental resilience, sleep disruption, and rehabilitation has supported research into objective neurological, behavioral, and digital biomarkers. This group is especially relevant for CNS biomarker applications tied to concussion assessment, post-traumatic stress symptoms, cognitive performance monitoring, and long-term neurological outcomes, while strict requirements for data security, interoperability, and ethical use shape implementation.

G7 countries remain central to CNS biomarker innovation due to advanced research institutions, regulatory expertise, laboratory infrastructure, and clinical trial networks. The group is influential in setting standards for biomarker validation, neuroimaging protocols, data quality, AI governance, and therapeutic monitoring in neurodegenerative and neuroinflammatory diseases. These countries also play a major role in evidence generation for Alzheimer's disease biomarkers, multiple sclerosis monitoring, Parkinson's disease research, and digital CNS measurement tools.

BRICS economies represent a major axis for future CNS biomarker development because they combine large patient populations, growing research capacity, and increasing investment in biotechnology and healthcare modernization. China, India, Brazil, Russia, and South Africa offer opportunities for diverse cohort development and real-world neurological data generation, which are essential for improving biomarker generalizability. However, infrastructure variability, regulatory differences, and uneven access to specialized neurology services require locally adapted implementation strategies.

The European Union benefits from coordinated research funding, multicountry clinical studies, strict data governance, and established frameworks for in vitro diagnostics, medical devices, and health technology assessment. These conditions support rigorous validation of CNS biomarkers and encourage harmonization of laboratory methods, imaging protocols, and real-world evidence collection. The EU's focus on ethical AI, data interoperability, and patient-centered care is particularly relevant for multimodal and digital CNS biomarkers.

ASEAN countries are advancing CNS biomarker relevance through expanding hospital networks, growing digital health adoption, and increasing attention to dementia, stroke, epilepsy, neurodevelopmental conditions, and mental health. Singapore plays a strong role in biomedical research and clinical translation, while Indonesia, Thailand, Malaysia, the Philippines, and Vietnam represent significant patient populations where scalable blood-based and digital biomarkers may help address specialist access gaps. Regional success depends on harmonized data standards, affordable diagnostics, and multicenter validation across diverse populations.

The GCC is strengthening CNS biomarker capabilities through investment in precision medicine, tertiary hospitals, genomics programs, and digital healthcare infrastructure. Countries in the group are well positioned to adopt advanced neurodiagnostics in specialized centers, particularly for dementia, multiple sclerosis, epilepsy, stroke, and rare neurological disorders. Local population studies, clinical workforce training, reimbursement clarity, and integrated referral pathways will be essential to ensure that biomarker tools move beyond premium care settings into broader clinical pathways.

Key Country Insights for CNS Biomarker Adoption

China is rapidly expanding CNS biomarker research through large hospital networks, national neuroscience initiatives, genomics capacity, and AI-enabled healthcare research. The United States leads in CNS biomarker translation through extensive clinical trial networks, advanced laboratory platforms, neuroimaging expertise, biobanking, and regulatory engagement around biomarker qualification and companion diagnostic pathways. Japan has deep expertise in aging-related neuroscience, dementia diagnostics, neuroimaging, and Parkinson's disease research, supported by one of the world's oldest populations. India has strong potential due to its large and diverse population, growing diagnostics sector, and increasing focus on neurological and mental health burden, though access differences between urban tertiary centers and rural regions remain important.

Germany is prominent in neurology, laboratory medicine, multiple sclerosis research, and hospital-based diagnostic infrastructure, supporting strong adoption conditions for validated CNS biomarkers. The United Kingdom has strong capabilities in dementia research, biobanking, neuroimaging, digital health studies, and population-linked health datasets. Australia contributes through longitudinal cohort research, brain health programs, clinical trial participation, and digital health readiness. France contributes through neuroscience institutes, imaging research, neurodegenerative disease programs, and coordinated clinical research networks. South Korea combines advanced healthcare infrastructure, biomedical research capacity, and digital technology strengths, supporting innovation in imaging, fluid biomarkers, and remote neurological monitoring.

Italy and Spain have established clinical neurology networks and active research in Alzheimer's disease, Parkinson's disease, epilepsy, stroke, and multiple sclerosis, with adoption shaped by regional care pathways and reimbursement processes. Canada contributes through neuroscience research, population-based health data, collaborative clinical programs, and public health-linked neurological datasets. Russia has scientific capacity in neuroscience and clinical neurology, although international collaboration dynamics and healthcare system structure influence the pace of global integration. Brazil is a leading Latin American contributor, supported by major academic centers, diverse populations, and expanding participation in neurology research. Mexico is strengthening diagnostic and research capabilities amid rising attention to dementia, stroke, epilepsy, and neurological care access.

Actionable Recommendations for CNS Biomarker Leaders

Industry leaders should prioritize clinically validated CNS biomarker solutions that address clear decision points, such as early detection, differential diagnosis, prognosis, treatment selection, monitoring of disease activity, safety assessment, and clinical trial enrichment. Development strategies should begin with robust analytical validation, including assay precision, reproducibility, pre-analytical controls, reference materials, and inter-laboratory comparability. Clinical validation should reflect real-world disease heterogeneity, comorbidities, age differences, sex differences, ethnicity, medication effects, disease stage, and care setting variation.

Organizations should build multimodal biomarker strategies that integrate blood-based testing, cerebrospinal fluid analysis, neuroimaging, cognitive measures, digital biomarkers, electrophysiology, and patient-reported outcomes where clinically justified. Data infrastructure should support interoperability with electronic health records, imaging archives, laboratory information systems, registries, and research databases. AI-enabled tools should be explainable, externally validated, continuously monitored, and governed by transparent model performance standards.

Commercial and clinical adoption require evidence beyond technical performance. Leaders should generate health economic evidence, workflow impact data, clinical utility studies, and physician education programs. Partnerships with academic centers, hospitals, patient registries, public health initiatives, and community-based research networks can strengthen dataset diversity and improve generalizability. Organizations should also prepare for evolving regulatory expectations around diagnostic claims, software as a medical device, data privacy, and post-market surveillance. Above all, equitable access should be embedded into product design, pricing, validation cohorts, and implementation planning.

Research Methodology for CNS Biomarker Analysis

This executive summary is developed through a structured secondary research approach focused on verified, data-backed sources relevant to central nervous system biomarkers. The methodology includes review and synthesis of peer-reviewed scientific literature, clinical guidelines, regulatory publications, public health data, biomarker qualification frameworks, disease-focused research consortium outputs, and publicly available information from recognized healthcare and neuroscience institutions. Priority is given to evidence from multicenter studies, systematic reviews, longitudinal cohorts, regulatory science documents, and clinically validated biomarker research.

The analysis evaluates CNS biomarkers across major modalities, including fluid biomarkers, neuroimaging markers, electrophysiological measures, digital biomarkers, genetic indicators, proteomic and metabolomic signatures, and AI-enabled multimodal models. Regional, group, and country insights are assessed based on healthcare infrastructure, research capacity, diagnostic access, clinical trial activity, regulatory maturity, aging demographics, digital health adoption, data governance, and neurological disease priorities. The methodology avoids speculative market sizing, revenue estimates, market share claims, and forecasting, focusing instead on evidence-based trends, adoption conditions, and strategic implications.

Quality control includes cross-checking claims across multiple credible sources, excluding unsupported promotional assertions, and distinguishing established clinical utility from emerging research potential. The resulting summary is designed to support executive decision-making, relevance, and strategic planning without relying on unverified projections.

Conclusion: Evidence-Led Growth in CNS Biomarkers

Central nervous system biomarkers are becoming foundational to the next phase of neurology, psychiatry, and CNS drug development. The strongest progress is occurring where validated biological measures are connected to clear clinical decisions, standardized workflows, and longitudinal patient monitoring. Blood-based biomarkers, advanced neuroimaging, electrophysiological measures, digital measures, and AI-enabled multimodal analysis are expanding what can be measured, but clinical value depends on reproducibility, interpretability, equitable validation, and integration into care pathways.

Regional dynamics show that North America and Europe remain influential in validation standards, regulatory science, and clinical trial infrastructure, while Asia-Pacific is rapidly strengthening research scale and translational capacity. Latin America, the Middle East, and Africa present important opportunities for inclusive biomarker development, particularly as global research recognizes the need for more diverse datasets and locally relevant implementation models.

The future of CNS biomarkers will be defined by evidence quality rather than technology novelty. Stakeholders that invest in rigorous validation, interoperable data systems, ethical AI, diverse cohorts, and real-world clinical utility will be best positioned to support earlier diagnosis, more precise treatment strategies, stronger clinical trial design, and more efficient CNS research programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Central Nervous System Biomarkers Market, by Type

  • 7.1. Introduction
  • 7.2. Molecular Biomarkers
    • 7.2.1. DNA Based Biomarkers
    • 7.2.2. RNA Based Biomarkers
    • 7.2.3. Protein Based Biomarkers
  • 7.3. Imaging Biomarkers
  • 7.4. Genetic Biomarkers
  • 7.5. Digital Biomarkers
  • 7.6. Metabolic Biomarkers

8. Central Nervous System Biomarkers Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Neurodegenerative Diseases
  • 8.3. Neurodevelopmental Disorders
  • 8.4. Psychotic Disorders

9. Central Nervous System Biomarkers Market, by Technology

  • 9.1. Introduction
  • 9.2. Immunoassay
    • 9.2.1. ELISA Based Biomarkers
    • 9.2.2. Multiplex Immunoassays
  • 9.3. Mass Spectrometry
    • 9.3.1. Proteomics Based Analysis
    • 9.3.2. Metabolomics Profiling
  • 9.4. Next-Generation Sequencing
    • 9.4.1. Whole Genome Sequencing
    • 9.4.2. RNA Sequencing

10. Central Nervous System Biomarkers Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnosis & Therapeutics
  • 10.3. Drug Discovery & Development
  • 10.4. Personalized Medicine
  • 10.5. Prognosis
  • 10.6. Research & Development

11. Central Nervous System Biomarkers Market, by End-User

  • 11.1. Introduction
  • 11.2. Academic Research Institutes
  • 11.3. Healthcare Providers
  • 11.4. Pharmaceutical & Biotechnology Companies
  • 11.5. Hospitals & Clinics

12. Central Nervous System Biomarkers Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Central Nervous System Biomarkers Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Central Nervous System Biomarkers Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Acumen Pharmaceuticals Inc.
  • 16.3. Agilent Technologies Inc.
  • 16.4. Alector Inc.
  • 16.5. Bio-Rad Laboratories Inc.
  • 16.6. Biogen Inc.
  • 16.7. C2N Diagnostics
  • 16.8. Charles River Laboratories International Inc.
  • 16.9. Eli Lilly and Company
  • 16.10. Eurofins Scientific
  • 16.11. F. Hoffmann-La Roche Ltd
  • 16.12. Fujirebio
  • 16.13. GE HealthCare Technologies Inc.
  • 16.14. IQVIA Holdings Inc.
  • 16.15. Johnson & Johnson Services Inc.
  • 16.16. Laboratory Corporation of America Holdings
  • 16.17. Merck KGaA
  • 16.18. Myriad Genetics Inc.
  • 16.19. Novartis AG
  • 16.20. PerkinElmer Inc.
  • 16.21. QIAGEN N.V.
  • 16.22. Quanterix Corp.
  • 16.23. Revvity Inc.
  • 16.24. Siemens Healthineers AG
  • 16.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MOLECULAR BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA BASED BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA BASED BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA BASED BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNA BASED BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA BASED BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNA BASED BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROTEIN BASED BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROTEIN BASED BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROTEIN BASED BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMAGING BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMAGING BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMAGING BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENETIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENETIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENETIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL METABOLIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METABOLIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL METABOLIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEURODEVELOPMENTAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEURODEVELOPMENTAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEURODEVELOPMENTAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PSYCHOTIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PSYCHOTIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PSYCHOTIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ELISA BASED BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ELISA BASED BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ELISA BASED BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLEX IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLEX IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLEX IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROTEOMICS BASED ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROTEOMICS BASED ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROTEOMICS BASED ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL METABOLOMICS PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL METABOLOMICS PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL METABOLOMICS PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNA SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HEALTHCARE PROVIDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEALTHCARE PROVIDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEALTHCARE PROVIDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 160. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 163. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 165. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 175. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 241. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 244. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 245. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 246. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 248. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 251. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 254. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 255. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 256. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 278. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 286. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 288. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 298. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 301. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 302. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 304. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 305. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 306. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 308. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 311. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 321. C